Stroke prevention: Managing modifiable risk factors

Silvia Di Legge, Giacomo Koch, Marina Diomedi, Paolo Stanzione, Fabrizio Sallustio

Research output: Contribution to journalArticle

Abstract

Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50 of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.

Original languageEnglish
Article number391538
JournalStroke Research and Treatment
DOIs
Publication statusPublished - 2012

Fingerprint

Stroke
Blood Vessels
Secondary Prevention
Atrial Fibrillation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antithrombins
Vitamin K
Angiotensin Receptor Antagonists
Carotid Stenosis
Angiotensin-Converting Enzyme Inhibitors
Anticoagulants
Antihypertensive Agents
Life Style
Therapeutics
Clinical Trials
Morbidity
Mortality
Health

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Stroke prevention : Managing modifiable risk factors. / Di Legge, Silvia; Koch, Giacomo; Diomedi, Marina; Stanzione, Paolo; Sallustio, Fabrizio.

In: Stroke Research and Treatment, 2012.

Research output: Contribution to journalArticle

Di Legge, Silvia ; Koch, Giacomo ; Diomedi, Marina ; Stanzione, Paolo ; Sallustio, Fabrizio. / Stroke prevention : Managing modifiable risk factors. In: Stroke Research and Treatment. 2012.
@article{99d6bf4d5d9442b6841f9cc18f7a6d4f,
title = "Stroke prevention: Managing modifiable risk factors",
abstract = "Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50 of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.",
author = "{Di Legge}, Silvia and Giacomo Koch and Marina Diomedi and Paolo Stanzione and Fabrizio Sallustio",
year = "2012",
doi = "10.1155/2012/391538",
language = "English",
journal = "Stroke Research and Treatment",
issn = "2090-8105",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Stroke prevention

T2 - Managing modifiable risk factors

AU - Di Legge, Silvia

AU - Koch, Giacomo

AU - Diomedi, Marina

AU - Stanzione, Paolo

AU - Sallustio, Fabrizio

PY - 2012

Y1 - 2012

N2 - Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50 of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.

AB - Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50 of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=84870160232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870160232&partnerID=8YFLogxK

U2 - 10.1155/2012/391538

DO - 10.1155/2012/391538

M3 - Article

C2 - 23213626

AN - SCOPUS:84870160232

JO - Stroke Research and Treatment

JF - Stroke Research and Treatment

SN - 2090-8105

M1 - 391538

ER -